171 results
Keyword Octreotide Remove keyword
-
List item
Orphan designation: Octreotide acetate for: Treatment of acromegaly
Date of designation: 05/08/2013, Positive, Last updated: 21/02/2022Octreotide acetate Overview On 5 August … Ltd, United Kingdom, for octreotide acetate (oral use) for treatment … of growth hormone) such as octreotide and lanreotide, and pegvisomant … -
List item
Orphan designation: Octreotide chloride for: Treatment of acromegaly
Date of designation: 12/06/2009, Positive, Last updated: 30/05/2018Octreotide chloride Overview On 12 June … to Camurus AB, Sweden, for octreotide chloride (lipid depot solution … of growth hormone) such as octreotide and lanreotide, and pegvisomant … -
List item
Orphan designation: Octreotide acetate for: Treatment of idiopathic intracranial hypertension
Date of designation: 10/12/2021, Positive, Last updated: 05/05/2022Octreotide acetate Overview This medicine … medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Octreotide acetate product-specific bioequivalence guidance
Last updated: 08/02/2019Octreotide acetate product-specific … Octreotide acetate product-specific … Octreotide acetate depot powder and …
-
List item
Referral: Sandostatin LAR and associated names
ocreotide, Article 30 referrals
Status: European Commission final decision, opinion/position date: 26/06/2014, EC decision date: 26/06/2014, Last updated: 27/06/2014contains the active substance octreotide. Octreotide is a synthetic substance … somatostatin. Like somatostatin, octreotide blocks the release of hormones … hormones. In Sandostatin LAR, octreotide is contained into microspheres … -
List item
Referral: Sandostatin and associated names
ocreotide, Article 30 referrals
Status: European Commission final decision, opinion/position date: 26/06/2014, EC decision date: 26/06/2014, Last updated: 27/06/2014contains the active substance octreotide. Octreotide is a synthetic substance … somatostatin. Like somatostatin, octreotide blocks the release of hormones … Sandostatin and associated names (octreotide, 0.05 mg/1 ml, 0.1 mg/1 ml … -
List item
Human medicine European public assessment report (EPAR): Signifor (updated)
pasireotide, Acromegaly; Pituitary ACTH Hypersecretion
Date of authorisation: 24/04/2012,
, Revision: 13, Authorised, Last updated: 14/06/2022
19% of patients receiving octreotide, another somatostatin analogue … the somatostatin analogues octreotide or lanreotide. Continuation … 19% of patients receiving octreotide, another somatostatin analogue … -
List item
Human medicine European public assessment report (EPAR): Lutathera
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017,
, , Revision: 6, Authorised, Last updated: 10/05/2022
for patients treated with octreotide, a medicine already approved … for patients treated with octreotide, a medicine already approved … -
List item
Orphan designation: pasireotide for: Treatment of acromegaly
Date of designation: 08/10/2009, Positive, Last updated: 13/05/2020of growth hormone) such as octreotide and lanreotide, and pegvisomant … respond to treatment with octreotide. These assumptions will need … of growth hormone) such as octreotide and lanreotide, and pegvisomant … -
List item
National expert: Karl Mikael Kälkner, Medical Products Agency (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 23.43 KB | PDF
111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res … Westlin JE. [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients … predict therapy outcome with octreotide treatment: a pilot study … -
List item
Orphan designation: Lutetium (177Lu) edotreotide for: Treatment of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 04/06/2014, Positive, Last updated: 05/09/2017treating GEP-NETs, including octreotide, everolimus, and sunitinib … treating GEP-NETs, including octreotide, everolimus, and sunitinib … -
List item
Orphan designation: Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt for: Treatment of acromegaly
Date of designation: 06/12/2012, Positive, Last updated: 09/02/2016of growth hormone) such as octreotide and lanreotide, as well as … responses in adenoma cells than octreotide and a potentially better … growth hormone) such as octreotide and lanreotide, as well as … -
List item
National expert: Wouter de Herder, European Medicines Agency (updated)
- Declaration of interests - 81.3 KB | PDF
- Curriculum Vitae - 105.61 KB | PDF
1992) Het insulinoom en octreotide. Ned Tijdschr Geneeskd 136 … Reubi JC, Krenning EP (1993) Octreotide and Related Somatostatin … -
List item
Orphan designation: Adeno-associated virus vector serotype 9 encoding the human GRN gene for: Treatment of frontotemporal dementia
Date of designation: 10/12/2021, Positive, Last updated: 03/05/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: Unesbulin for: Treatment of soft tissue sarcoma
Date of designation: 10/12/2021, Positive, Last updated: 03/05/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
National expert: Jeroen Dekervel, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 81.49 KB | PDF
- Curriculum Vitae - 23.29 KB | PDF
-
List item
Orphan designation: Ribonucleoprotein complex composed of two sgRNA and a Cas9 nuclease targeting the human COL7A1 gene for: Treatment of epidermolysis bullosa
Date of designation: 10/12/2021, Positive, Last updated: 20/04/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol- 3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl) phenyl]acetamide for: Treatment of epileptic encephalopathy with continuous spike-and-wave during sleep
Date of designation: 10/12/2021, Positive, Last updated: 21/04/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine for: Treatment of acute lymphoblastic leukaemia
Date of designation: 10/12/2021, Positive, Last updated: 28/04/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment for: Treatment of primary sclerosing cholangitis
Date of designation: 10/12/2021, Positive, Last updated: 28/04/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: Cedazuridine, decitabine for: Treatment of acute myeloid leukaemia
Date of designation: 10/12/2021, Positive, Last updated: 28/04/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: Norrin (25-133), Lys86Pro for: Treatment of familial exudative vitreoretinopathy
Date of designation: 10/12/2021, Positive, Last updated: 03/05/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: 2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanoylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl ... for: Treatment of cystic fibrosis
Date of designation: 10/12/2021, Positive, Last updated: 05/05/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: Troriluzole hydrochloride for: Treatment of spinocerebellar ataxia
Date of designation: 10/12/2021, Positive, Last updated: 05/05/2022medicine is expected to work Octreotide mimics the biological activity … these somatostatin receptors, octreotide is expected to reduce intracranial … -
List item
Orphan designation: (R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea (ceclazepide) for: Treatment of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 14/12/2015, Positive, Last updated: 02/03/2021treating GEP-NETs, including octreotide and lanreotide for the management … treating GEP-NETs, including octreotide and lanreotide for the management …